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Background: The Pooled Cohort Risk Equation was introduced by the American College of Cardiology (ACC) and
American Heart Association (AHA) 2013 in their Blood Cholesterol Guideline to estimate the 10-year atherosclerotic
cardiovascular disease (ASCVD) risk. However, absence of Asian ethnicity in the contemporary cohorts and limited
studies to examine the use of the risk score limit the applicability of the equation in an Asian population. This study
examines the validity of the pooled cohort risk score in a primary care setting and compares the cardiovascular risk
using both the pooled cohort risk score and the Framingham General Cardiovascular Disease (CVD) risk score.
Methods: This is a 10-year retrospective cohort study of randomly selected patients aged 40–79 years. Baseline
demographic data, co-morbidities and cardiovascular (CV) risk parameters were captured from patient records in
1998. Pooled cohort risk score and Framingham General CVD risk score for each patient were computed. All ASCVD
events (nonfatal myocardial infarction, coronary heart disease (CHD) death, fatal and nonfatal stroke) occurring from
1998–2007 were recorded.
Results: A total of 922 patients were studied. In 1998, mean age was 57.5 ± 8.8 years with 66.7% female. There
were 47% diabetic patients and 59.9% patients receiving anti-hypertensive treatment. More than 98% of patients
with pooled cohort risk score ≥7.5% had FRS >10%. A total of 45 CVD events occurred, 22 (7.2%) in males and 23
(3.7%) in females. The median pooled cohort risk score for the population was 10.1 (IQR 4.7-20.6) while the actual
ASCVD events that occurred was 4.9% (45/922). Our study showed moderate discrimination with AUC of 0.63. There
was good calibration with Hosmer-Lemeshow test χ2 = 12.6, P = 0.12.
Conclusions: The pooled cohort risk score appears to overestimate CV risk but this apparent over-prediction could
be a result of treatment. In the absence of a validated score in an untreated population, the pooled cohort risk
score appears to be appropriate for use in a primary care setting.
Keywords: Pooled cohort risk score, Atherosclerotic cardiovascular disease, Validation, Asian population,
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The American College of Cardiology (ACC) and American
Heart Association (AHA) released a new guideline on
blood cholesterol management in November 2013. This
guideline introduced the new pooled cohort risk equation
to estimate 10-year atherosclerotic cardiovascular dis-
ease (ASCVD) risk, which includes nonfatal myocardial* Correspondence: chiayc@um.edu.my
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unless otherwise stated.infarction (MI), coronary heart disease (CHD) death,
nonfatal and fatal stroke [1]. The pooled cohort risk
equation was derived from four major population-based
cohort studies in the United States involving white and
black Americans and this new risk tool was further vali-
dated by two external cohorts: Reasons for Geographic
and Racial Differences in Stroke (REGARDS) and Multi-
Ethnic Study of Atherosclerosis (MESA) [2,3]. This pooled
cohort risk score serves as a guide to help clinician in de-
ciding statin initiation for patients with mildly elevated
CV risk. Statin is recommended as primary prevention for
those non-diabetic patients with LDL 90-189 mg/dl and
pooled cohort risk score ≥7.5%.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tion of the pooled cohort risk score. The applicability of
the pooled cohort risk score is being questioned because
it is perceived to overestimate CV risk due to the lower
cut-off point of 7.5% and that more patients will need to
be treated with statins if the pooled cohort risk score is
applied [4-6].
Absence of Asian ethnicity in the contemporary co-
horts and external cohorts limit the applicability of the
pooled cohort risk score in the Asian population. Until
recently very few studies examined the use of pooled co-
hort risk score in different populations. Hence, our aim
was to validate the use of the pooled cohort risk equa-
tion in an Asian population. We also compared the CV
risk of our population using both the pooled cohort risk
score and the Framingham General CVD risk score.
Methods
Setting
This study is a 10-year retrospective cohort study of ran-
domly selected patients registered with an outpatient
primary care clinic of University Malaya Medical Centre
(UMMC). The hospital is located in Kuala Lumpur, the
capital of Malaysia. The main ethnic groups in this popula-
tion are Malay, Chinese and Indian. The outpatient clinicFigure 1 Flowchart of patients included in the analysis.is under the Department of Primary Care Medicine which
is run by 14 family medicine specialists and 30 vocational
trainees in family medicine. Ethics approval was obtained
from the Ethics Committee of the institution.
Study population
There were 1536 patients in our original cohort. We ex-
cluded patients aged <40 or aged >79 (n = 83) as this
was out of the age range of the pooled cohort risk score
calculator. Out of 1453 patients, 526 (36.2%) patients
were also excluded as they did not have all the variables
needed to calculate the pooled cohort risk score. Another
5 patients was excluded as we could not ascertain their
CVD status by the end of 2007. Hence a total of 922 pa-
tients (63.5%) were eligible for analysis (Figure 1). Our
follow-up rate over the 10-years was 95% (871/922) with
only 51 (5%) patients who did not come for follow up.
Inclusion criteria
Adults aged 40–79 without clinical ASCVD who were
already registered in our centre in 1998.
Exclusion criteria
Patients who did not have all the variables to calculate
the pooled cohort risk score at baseline were excluded.
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ASCVD event.
Data collection
Random numbers were generated by computer based on
the patients’ registration number with the clinic. Base-
line data was collected in 1998 and follow-up data
collected in 2007, a 10-year interval. We extracted the
patients’ information from their paper-based records
manually. Socio-demograhic data and co-morbidities were
recorded.
A pooled cohort risk score for each patient was com-
puted using the online Pooled Cohort Risk Equation
provided by the American Heart Association [7]. For the
variable race, we used ‘White or others’ for our study
population. The Framingham risk score (FRS) for 10-year
risk of cardiovascular disease (CVD) was also calcu-
lated based on the Framingham General CVD risk
score chart [8]. All the variables needed for calculation
of both the scores are shown in Table 1. ASCVD
events in the 10-year period (1998–2007) were cap-
tured. ASCVD event is defined as nonfatal myocardial
infarction (MI), CHD death, nonfatal and fatal stroke
[1]. ASCVD events in our cohort were based on the
clinicians’ diagnosis supported by the relevant investi-
gations. For those who defaulted and did not completeTable 1 Variables for pooled cohort risk score and
Framingham general CVD risk score





Total cholesterol (mg/dl) Total cholesterol (mg/dl)





Treatment for high blood
pressure




CVD events Nonfatal myocardial
infarction
Nonfatal myocardial infarction
CHD death CHD death
Nonfatal stroke Angina




CVD Cardiovascular Disease; HDL high density lipoprotein; CHD cardiovascular
heart disease.their subsequent 10 year follow-up at our clinic (n = 31)
we traced and examined their case records with the main
hospital to determine their CVD outcome. For those
patients who did not attend our clinics or hospital after
being entered into our study, we called the patient or
their family individually (n = 20) to ascertain their CVD
status. We were not able to ascertain CVD outcome in
only 5 patients.
Blood Pressure (BP) was measured by our attending
doctor using a mercury sphygmomanometer as part of
the daily routine practice. Diagnosis of hypertension is
made in accordance with standard recommendations i.e.
BP ≥140/90 mmHg based on at least 2 blood pressure
measurements at least 2 weeks apart [9]. The use of
anti-hypertensive agents was recorded as well. Diabetes
mellitus was defined as documented by the attending
physician or the use of hypoglycaemic agents or both.
Smokers were defined if they were still smoking currently.
Non-smokers were those who never smoked or currently
not smoking regardless of when they had stopped smok-
ing. Total cholesterol, LDL and HDL cholesterol were also
collected. All blood tests were performed in our teaching
hospital’s laboratory which is certified by the Royal College
of Pathologists of Australasia standards. Statin use in 1998
and 2007 was recorded.
Statistical analysis
All statistical analysis was done using the Statistical
Package for Social Sciences (SPSS version 15). Categorical
data are reported as proportions (percentage). Mean was
used for continuous variables that were normally distrib-
uted. Median and interquartile range were used for vari-
ables that were not normally distributed.
Discrimination
Discrimination is defined as the ability of a risk predic-
tion model to accurately rank order individuals (i.e. are
individuals with higher predicted risk more likely to have
events.) We used receiver operating characteristic (ROC)
curve to determine the discriminative power of the pooled
cohort risk score. The area under the curve (AUC), also
known as c-index, was used as a measure of how well the
pooled cohort risk score can discriminate. Discrimination
is defined as good when the c index is closer to 1 whereas
a value of 0.5 implies that the risk score tool is no better
than chance [10].
Calibration
Calibration was used to assess whether the observed
10-year ASCVD events differed significantly from pre-
dicted [10]. The calibration of the pooled cohort risk
score was determined using Hosmer-Lemeshow test [11].
A χ2 value of greater than 20 or a p value of less than
0.05 indicates poor calibration.
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NRI was used to quantify improvement offered by pooled
cohort risk score compared to Framingham General CVD
risk score. We adopted the approach proposed by Pencina
et al. for the NRI analysis [12].
Results
A total of 922 patients were eligible for this study.
Table 2 shows the clinical characteristics of the study
population at baseline in 1998. Overall, the mean age of
the population was 57.5 ± 8.8 years and about two-thirds
of the population was female (66.7%, n = 615). The major
ethnic group was Chinese (46.1%, n = 425), followed by
Indian (29.8%, n = 275) and Malay (22.7%, n = 210).
Nearly half of the patients were diabetic (47%). 87.5%
(n = 371) of these diabetic patients were receiving treat-
ment with either oral hypoglycaemic agents and/or insu-
lin. The mean systolic BP was 140.9 ± 18.6 mmHg and
more than half of the population was treated with anti-
hypertensive agents. Only 9.7% of the population (n = 90)
received statin therapy in 1998. We also compared the
baseline characteristics for those who were entered into
our analysis to the patients who were excluded. Basically
there was no substantial difference between their baseline
characteristics.Table 2 Comparison of CV risk factors in 1998 and 2007
Clinical characteristics 1998 2007
Age, year (mean) 57.5 ± 8.8 67.5 ± 8.8
Sex, female (n, %) 615 (66.7) 615 (66.7)
Ethnicity (n, %)
- Malay 210 (22.7) 210 (22.7)
- Chinese 425 (46.1) 425 (46.1)
- Indian 275 (29.8) 275 (29.8)
- Others 12 (1.4) 12 (1.4)
Diabetes mellitus (n, %) 424 (47.0) 528 (57.3)
- HbA1c, % (mean) 7.7 ± 1.8 7.5 ± 1.6
- DM controlled with HbA1c ≤6.5% (n, %) 110 (11.9) 163 (17.7)
Systolic BP, mmHg (mean) 140.9 ± 18.6 135.1 ± 16.6
- Use of anti-hypertensive agents (n, %) 552 (59.9) 760 (82.4)
- BP controlled SBP ≤140 mmHg (n, %) 568 (61.6) 681 (73.9)
- RAS blocker use (n, %) 66 (7.2) 371 (40.2)
Total cholesterol, mg/dl (mean) 234.8 ± 42.3 190.9 ± 37.2
HDL cholesterol, mg/dl (mean) 47.6 ± 14.2 49.6 ± 12.5
LDL cholesterol, mg/dl (mean) 143.1 ± 40.7 115.5 ± 31.6
Statin use in 1998 (n, %) 90 (9.7) 587 (63.7)
Smoker (n, %) 56 (6.1) 56 (6.1)
Mean ± Standard deviation.
CV cardiovascular, DM diabetes mellitus, BP blood pressure, SBP systolic blood
pressure, RAS renin-angiotensin system, HDL high density cholesterol, LDL low
density cholesterol.Table 2 also shows the change in CVD risk factors at
the end of 10 years. The number of diabetic patients
increased from 47.0% to 57.3% but HbA1c control
improved from a mean of 7.7% to 7.5%. The mean sys-
tolic blood pressure was reduced by 5.8 mmHg, from
140.9 mmHg to 135.1 mmHg. The number of patients
who had controlled BP with systolic BP ≤140 mmHg in-
creased from 61.6% to 73.9%. There was an increase in the
use of renin-angiotensin system (RAS) blockers from 7.2%
to 40.2%. The number of patients receiving statin increased
significantly from 9.7% to 63.7% in 2007. There was also
improvement in the lipid profile of patients at the end of
10 years compared to baseline. Mean of total cholesterol
was reduced from 234.8 mg/dl to 190.9 mg/dl while the
mean HDL increased from 47.6 mg/dl to 49.6 mg/dl.
Table 3 compares the 10-year CV risk of our popula-
tion at baseline using both the FRS and the pooled co-
hort risk score. For those with pooled cohort risk score
of 7.5-9.9%, 98.8% of them have FRS ≥10%. Whereas in
those patients with pooled cohort risk score 10–19.9%
and ≥20%, 99.6% of them have FRS ≥10%. Hence, we
conclude that more than 98% of patients with pooled co-
hort risk score ≥7.5% have a FRS of >10%. In those with
pooled cohort risk score of <7.5%, two-thirds have FRS
of >10%. Only 13.4% (124/922) have low risk in both risk
scores.
Table 4 shows the comparison of predicted and ob-
served pooled cohort risk score in 1998 and ASCVD
events in the 10-year interval from 1998 to 2007 in our
primary care patients. The median pooled cohort risk
score for the study population was 10.1% (IQR 4.7-20.6).
The actual number of ASCVD events that occurred in
the 10 years was 45 (45/922 = 4.9%) while the predicted
was 93. In men, their median pooled cohort risk score
was 21.1% while the events that occurred was 22 (7.2%).
In women, their median pooled cohort risk score 6.7%
while the event that occur was 23 (3.7%). Similarly the
events rate was twice as high in men (7.2%) than women
(3.7%). Interestingly, we noticed that 8 (2.2%) ASCVD
events occurred in those patients with pooled cohort
risk score ≤7.5% (N = 367). We analysed the CV risk for
this group of patients and found out that 36% had DM
and 51% hypertension. Over the 10-year period, the
prevalence of DM and hypertension increased to 49%
and 80.9% respectively. The statin use for this low risk
group of patients was increased from 10.4% to 68.1%.
The AUC for pooled cohort risk score was 0.63 show-
ing moderate discrimination as shown in Figure 2. The
calibration for pooled cohort risk score was good as the
Hosmer-Lemeshow test result was χ2 = 12.6, P = 0.12.
We also calculated the Net Reclassification Index (NRI)
and the NRI is 3.1% (p = 0.001). This indicates that the
pooled cohort risk score provided 3.1% more net reclas-
sification improvement.
Table 3 Comparison of 10-year cardiovascular risk in 1998 between the pooled cohort risk score and Framingham
general CVD risk score
10-year CVD risk (Framingham
general CVD risk score)
10-year ASCVD risk (pooled cohort risk score)
(N = 922)
<7.5% 7.5-9.9% 10.0-19.9% ≥20% Total
N (% of total N) N (% of total N) N (% of total N) N (% of total N)
<10% 124 (34.0) 1 (1.2) 1 (0.4) 1 (0.4) 128
10-20% 197 (53.7) 35 (40.7) 44 (19.3) 2 (0.8) 278
>20% 45 (12.5) 50 (58.1) 183 (80.3) 238 (98.8) 520
Total 366 86 228 241 922
ASCVD: atherosclerosis cardiovascular disease; CVD cardiovascular disease.
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risk score and ASCVD events according to ethnicity.
The pooled cohort risk score discriminates moderately
well for Malay race (AUC 0.73, p = 0.011) but not for the
Chinese and Indian.
Discussion
A very recent study validated the pooled cohort risk score
in a US population and found it to work very well [2]. OurTable 4 Comparison of predicted and observed pooled









Median score: 10.1% 922 45 (4.9) 93 (10.1)
(95% CI 4.7-20.6)
- <7.5% 367 8 (2.2) 14 (3.8)
- 7.5-9.9% 86 6 (7.0) 7 (8.4)
- 10-19.9% 228 12(5.3) 32 (13.9)
- ≥20% 241 10(7.9) 73 (30.5)
Male
Median score: 21.1% 307 22 (7.2) 64 (21.1)
(95% CI 12.0-31.9)
- <7.5% 32 0 1 (4.5)
- 7.5-9.9% 19 1 (5.3) 2 (8.2)
- 10-19.9% 92 6 (6.5) 13 (14.3)
- ≥20% 164 15 (9.1) 51 (31.1)
Female
Median score: 6.7% 615 23 (3.7) 41 (6.7)
(95% CI 3.3-13.0)
- <7.5% 335 8 (2.4) 12 (3.6)
- 7.5-9.9% 67 5 (7.5) 6 (8.4)
- 10-19.9% 136 6 (4.4) 18 (13.5)
- ≥20% 77 4 (5.2) 22 (28.2)
CI = Confidence Interval.study showed that the pooled cohort risk score has moder-
ate discrimination and good calibration in an Asian popu-
lation. One possible explanation of our finding of only
moderate discrimination could be because of the high
prevalence of patients with CV risk factors (i.e. the high
prevalence of diabetes and hypertension seen) and there-
fore a clustering of patients with higher risk and fewer pa-
tients with lower risk. Hence in a general population of
subjects with a wider range of CV risk, this risk prediction
model may give a better discrimination.
However, the number of observed events was fewer
than predicted. This apparent over-estimation could be
because of treatment which would result in a reduction
of ASCVD events. As seen in our study, the number of
patients receiving statin therapy increased from 9.7%
(n = 90) to 63.7% (n = 587) over the 10-year period. Besides
the increase in statin use other CV risk factors were also
improved where the mean systolic blood pressure, meanFigure 2 ROC and AUC for pooled cohort risk score.
Table 5 Comparison pooled cohort risk score and ASCVD events according to ethnicity
Pooled cohort risk score (%) ASCVD event AUC (95% CI) p-value
Observed Predicted
N (%) N
Overall (N = 922) 10.1 45 (4.9) 93 0.632 (0.557,0.70) 0.003
Malay (N = 210) 7.9 10 (4.8) 17 0.737 (0.641,0.834) 0.011
Chinese (N = 425) 10.8 21 (4.9) 46 0.625 (0.512,0.737) 0.054
Indian (N = 275) 10.0 14 (5.1) 28 0.576 (0.417,0.736) 0.335
AUC = Area under curve.
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the 10-year period. Control rate for blood pressure and
diabetes as well as use of RAS blockers also increased [13].
Studies have shown that a reduction of 10 mmHg of blood
pressure can result in a reduction of 25% of CHD, 45% of
stroke and 55% of heart failure [14,15]. Furthermore, a 1%
decrease in HbA1c level can lead to a reduction of fatal
and non-fatal MI by 14%, peripheral vascular disease by
43% and heart failure by 16% [16]. For LDL cholesterol
level, every 38 mg/dl of LDL reduction associated with
20% reduction of CVD events [17]. In view of the treat-
ment given and the control rates achieved, there would be
substantial improvement of all the CV risk factors in our
study population over the 10-year period, leading to signifi-
cant reduction of ASCVD events.
One of the reasons the pooled cohort risk score was
introduced is because it is derived from a more diverse
population when compared to FRS which is based on a
more homogenous cohort. While the pooled cohort risk
score has not been widely validated yet, the Framingham
General CVD risk score has been well studied even out-
side the US [18-23]. However, NRI of 3.1% in our study
showed there was no substantial improvement of the
pooled cohort risk score over the FRS suggesting that
both risk scores are equivalent.
There is general concern that using the lower thresh-
old of 7.5% based on the pooled cohort risk score to de-
termine the need for statin therapy will mean that more
patients will be treated with statin [10]. However some re-
ports suggest otherwise [24,25]. Furthermore, our study
showed that in those with pooled cohort risk score of 7.5-
9.9%, almost all had a FRS of >10% suggesting that this
new AHA/ACC recommendation may be appropriate.
The proportion of patients with low risk in our study
is small because our cohort is made up of actual patients
whose CV risks are expected to be higher and hence
there will be fewer people with low risk in our cohort.
However, the individuals that were identified as low risk
by pooled cohort risk score did actually have ASCVD
events. This group of low risk patients was relatively
younger with mean age of 50.8 years. Even though their
risks were calculated to be low at baseline, some of themdid have diabetes (32.7%) and 51% have hypertension.
Furthermore these patients’ risk increased over the
10-year period, with aging and with more of them develop-
ing diabetes (49%) and hypertension (80.6%). Statin use
also increased amongst these low risk patients suggesting
that they developed dyslipidaemia along the way thus in-
creasing their risk for CV events.
Interestingly, in those patients with pooled cohort risk
score <7.5%, about two-thirds of these patients have a
FRS of >10%. This discrepancy could be because the
FRS predicts not just only fatal and non fatal stroke,
nonfatal MI and CHD death used in the pooled cohort
risk score, but also include angina, cardiac failure and
peripheral arterial disease. Hence the FRS score would
appear magnified when compared to pooled cohort risk
score.
Strengths and limitations
Our long study period allowed us to obtain data on
ASCVD events over 10 years. This is in accordance with
the pooled cohort risk equation which was designed to
estimate a 10-year ASCVD risk. Our study was con-
ducted in a primary care setting where most patients
have not had any ASCVD events yet. And this is the
group of patients who will be the main target for risk
stratification so that primary prevention can be initi-
ated appropriately. Besides that, we were able to com-
pare the characteristics of those with missing data
and those included in the analysis and found no clin-
ical differences between them, suggesting there was no
substantial bias.
As this is a retrospective cohort study, recall bias in
the actual CV events may occur especially for those pa-
tients who defaulted follow-up in our centre and there-
fore without proper documentation of events.
Conclusion
In our study, when compared to using the FRS, the
pooled cohort risk score using a lower threshold of 7.5%
risk does not appear to overestimate CV risk. However
the pooled cohort risk score appears to overestimate
absolute CV risk as the observed events are less than
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sult of treatment. Hence, in the absence of validation of
the pooled cohort risk score in an untreated population,
the pooled cohort risk score is appropriate for use in a
primary care setting.
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